Telix Pharmaceuticals (NASDAQ:TLX) Reaches New 52-Week Low – What’s Next?

Telix Pharmaceuticals Limited (NASDAQ:TLX) shares hit a new 52-week low during trading on Wednesday . The company traded as low as $7.29 and last traded at $7.26, with a volume of 11340 shares changing hands. The stock had previously closed at $7.73.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on TLX shares. Wall Street Zen lowered Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a report on Wednesday. Canaccord Genuity Group raised shares of Telix Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 6th. Finally, Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $21.00.

Telix Pharmaceuticals Stock Performance

The company’s 50-day moving average price is $8.48 and its 200 day moving average price is $10.42.

Institutional Trading of Telix Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of TLX. Rhumbline Advisers lifted its stake in shares of Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after buying an additional 1,392 shares during the period. IHT Wealth Management LLC purchased a new position in Telix Pharmaceuticals during the second quarter worth approximately $213,000. Blair William & Co. IL acquired a new position in Telix Pharmaceuticals during the second quarter worth $217,000. Private Advisor Group LLC lifted its stake in Telix Pharmaceuticals by 67.3% in the 3rd quarter. Private Advisor Group LLC now owns 42,112 shares of the company’s stock valued at $403,000 after buying an additional 16,945 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in Telix Pharmaceuticals during the 2nd quarter worth $297,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.